Bristol Myers Squibb (BMY)
(Delayed Data from NYSE)
$41.48 USD
+0.60 (1.47%)
Updated Jun 7, 2024 04:00 PM ET
After-Market: $41.48 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth D Momentum B VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
BMY 41.48 +0.60(1.47%)
Will BMY be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for BMY based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for BMY
Replimune (REPL) Gains on Positive Data From Melanoma Study
Bristol Myers (BMY) Reports Positive Data on Breyanzi, Opdivo (Revised)
BMY: What are Zacks experts saying now?
Zacks Private Portfolio Services
Bristol Myers (BMY) Reports Positive Data on Breyanzi, Opdivo
Why Bristol Myers Squibb (BMY) Outpaced the Stock Market Today
Bristol Myers (BMY) Gets EC Nod for Opdivo Label Expansion
Other News for BMY
Bristol Myers Squibb wins antitrust case against insurers regarding generics
AstraZeneca dominates, Merck’s Keytruda beaten as ASCO 2024 concludes
Investing $1 Million In An 8-Fund Portfolio Vs. An All-Stock Portfolio
The 7 Most Undervalued Under-$50 Stocks to Buy in June 2024
Geron: Innovative Rytelo Enters A Challenging MDS Market